Dhokia B, Pectasides D, Self C, Habib N A, Hershman M, Wood C B, Munro A J, Epenetos A A
Br J Cancer. 1986 Dec;54(6):885-9. doi: 10.1038/bjc.1986.257.
A new, simple and sensitive low pH ELISA method has been developed to measure serum levels of tumour associated antigens detectable by monoclonal antibodies HMFG1 and HMFG2. We examined sera from healthy controls, patients with neoplastic and non-neoplastic conditions of breast, liver and gastrointestinal tract. The majority of patients with metastatic breast cancer had elevated serum antigens (69% HMFG1, 72% HMFG2) compared to healthy controls (6.3% HMFG1, 3.0% HMFG2) or patients with benign breast disease (17% HMFG1, 4% HMFG2). There was no discrimination using these assays between patients with neoplastic and non-neoplastic conditions of liver and gastrointestinal tract. This new method promises to be of value in the assessment and management of patients with breast cancer.
一种新的、简单且灵敏的低pH酶联免疫吸附测定（ELISA）方法已被开发出来，用于测量可被单克隆抗体HMFG1和HMFG2检测到的肿瘤相关抗原的血清水平。我们检测了来自健康对照者、患有乳腺、肝脏和胃肠道肿瘤及非肿瘤疾病患者的血清。与健康对照者（HMFG1为6.3%，HMFG2为3.0%）或患有良性乳腺疾病的患者（HMFG1为17%，HMFG2为4%）相比，大多数转移性乳腺癌患者的血清抗原水平升高（HMFG1为69%，HMFG2为72%）。使用这些检测方法无法区分患有肝脏和胃肠道肿瘤及非肿瘤疾病的患者。这种新方法有望在乳腺癌患者的评估和管理中发挥作用。
